eCommons@AKU
Department of Medicine

Department of Medicine

7-26-2022

The impact of the COVID-19 pandemic on patients with chronic
liver disease: Results from the Global Liver Registry
Zobair M. Younossi
Inova Fairfax Medical Campus, Falls Church, Virginia

Yusuf Yilmaz
Marmara University, Istanbul

Mohamed El-Kassas
Helwan University, Cairo

Ajay Duseja
Postgraduate Institute of Medical Education and Research, Chandigarh

Saeed Hamid
Aga Khan University, saeed.hamid@aku.edu

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Immune System Diseases Commons, Infectious Disease Commons, Patient Safety
Commons, Pulmonology Commons, and the Virus Diseases Commons

Recommended Citation
Younossi, Z. M., Yilmaz, Y., El-Kassas, M., Duseja, A., Hamid, S., Esmat, G., Méndez-Sánchez, N., Chan, W.
K., Singal, A. K., Lam, B. (2022). The impact of the COVID-19 pandemic on patients with chronic liver
disease: Results from the Global Liver Registry. Hepatology communications.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/658

Authors
Zobair M. Younossi, Yusuf Yilmaz, Mohamed El-Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahum
Méndez-Sánchez, Wah Kheong Chan, Ashwani K. Singal, and Brian Lam

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/658

Received: 1 February 2022

|

Accepted: 30 May 2022

DOI: 10.1002/hep4.2048
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Abstract
Patients with preexisting chronic liver disease (CLD) may experience a
substantial burden from both coronavirus 2019 (COVID-
19) infection and
pandemic-related life disruption. We assessed the impact of the COVID-19
pandemic on patients with CLD. Patients enrolled in our Global Liver Registry
were invited to complete a COVID-19 survey. As of June 2021, 2500 patients
(mean age ± SD, 49 ± 13 years; 53% men) from seven countries completed the
survey. Of all survey completers, 9.3% had COVID-19. Of these patients, 19%
were hospitalized, 13% needed oxygen support, but none required mechanical ventilation. Of all patients including those not infected with COVID-19,
11.3% reported that the pandemic had an impact on their liver disease, with
73% of those reporting delays in follow-up care. The Life Disruption Event
Perception questionnaire confirmed worsening in at least one area (food/nutrition, exercise, social life, vocation/education, financial situation, housing,
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or health care) in 81% and 69% of patients with and without a history of
COVID-19, respectively (p = 0.0001). On a self-assessed Likert health score
scale (range, 1–10; 10 indicates perfect health), patients with a COVID-19 history scored lower (mean ± SD, 6.7 ± 2.2 vs. 7.4 ± 2.2, respectively; p < 0.0001)
despite reporting similar health scores if there was no pandemic (mean ±
SD, 8.5 ± 1.4 vs. 8.4 ± 1.6, respectively; p = 0.59). After adjustment for country of enrollment, liver disease etiology and severity, age, sex, body mass
index, diabetes, and history of psychiatric comorbidities, COVID-
19 was
found to be independently associated with lower self-assessed health scores
(beta = −0.71 ± 0.14; p < 0.0001). The COVID-19 pandemic resulted in a substantial burden on the daily life of patients with CLD.

I NTRO DUCTI O N
Chronic liver disease (CLD) is a major cause of mortality, morbidity, and resource utilization worldwide.[1,2]
At present, liver cirrhosis with its related complications
is the ninth most common cause of death globally.[3]
The most common etiologies of CLD include alcohol-
related liver disease (ALD), viral hepatitis B (HBV) and C
(HCV), and nonalcoholic fatty liver disease (NAFLD).[2]
Since its first description in early 2020, we have
learned that coronavirus 2019 (COVID-
19) does not
spare any organ system.[3–9] In fact, it has been reported
that up to 50% of patients with COVID-19 can develop
some form of hepatic dysfunction that may eventually
result in poor outcomes.[3,7,9] Additionally, patients with
NAFLD who were hospitalized with COVID-
19 were
reported to be sicker on admission and require more
hospital resource utilization than those without liver
disease. Higher fibrosis-4 (FIB-4) and multimorbidity
scores, morbid obesity, older age, and hypoxemia on
admission have been identified as independent predictors of mortality in patients with CLD who developed
COVID-19.[8]
In addition to severe clinical outcomes, once infected, patients with CLD may experience pandemic-
related life disruption. This could include difficulties in
accessing routine care and disruption of personal support networks, daily routines, habits, and mental stress.
The aim of this study was to characterize the impact of
COVID-19 on patients with CLD by using data from the
preexisting Global Liver Registry (GLR).

M ATER I A LS A N D M ETH O DS
Patient population
For the purpose of this study, patients enrolled in our
GLR[10] were invited between May 2020 and May 2021
to complete a specifically designed survey. The GLR

was established in 2016, enrolling patients with three
common types of CLD: chronic hepatitis B (CHB),
chronic hepatitis C (CHC), and NAFLD/nonalcoholic
steatohepatitis (NASH). As of 2022, the GLR enrolled
patients with CLD from 18 countries from all continents.
Patients were not enrolled if they had CLD etiology other
than the three listed above, decompensated cirrhosis,
hepatocellular carcinoma (HCC) and other liver malignancies, or liver transplantation. Clinicodemographic
data (age, sex, race, site of enrollment) were collected
following inclusion in the GLR, along with most recent
height and weight used to calculate body mass index
(BMI), relevant elements of the patient's past medical
history, and laboratory data needed to calculate FIB-4
scores (liver enzymes and platelet count). The study
was approved by the Western Institutional Review
Board and by institutional review boards or similar supervisory institutions from each participating site. All
patients provided informed consent before being enrolled in the GLR.

The Covid-Global Registry
Questionnaire survey
The Covid-Global Registry Questionnaire (Covid-GRQ)
survey consisted of 23 items (Supporting Material 1).
Questions included whether patients had been infected with COVID-19 and the characteristics of their
illness if they had been infected (duration of illness in
days, symptoms, diagnostics, and treatment received).
In addition, all GLR enrollees, regardless of whether
they had been infected with COVID-19, were asked to
answer questions about the overall effect of the pandemic. Specifically, patients were asked whether the
COVID-19 pandemic had any impact on their liver disease condition, whether they had difficulties in accessing medical care during the pandemic, and whether
supportive care was needed in order to cope with the
COVID-19 pandemic. All patients were also asked to
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rate their overall health given the pandemic situation
and, separately, if there were no pandemic, both on
a 1–10 Likert scale (with 10 indicating perfect health).
Finally, the Covid-GRQ included a Life Disruption Event
Perception (LDEP) questionnaire with two multidomain
questions that asked about the degree of change in the
patient's life and habits (scored on a Likert scale from
0 “Not at all changed” to 6 “Completely changed”) and
how the patient viewed the changes compared to before the pandemic (scored on a scale from −3 “Much
worse” to +3 “Much better”).[11] Both questions covered the following seven aspects of daily life: Food &
Nutrition, Exercise & Movement, Social & Interpersonal,
Vocational & Educational, Financial Stability, Housing,
and Health Care. The scores across all the categories
were averaged to yield the LDEP change and LDEP
trend scores, respectively.

Statistical analysis
Demographic and relevant clinical parameters as well
as Covid-GRQ responses and LDEP scores were summarized as means ± SDs or frequencies (percentages)
and were compared between patients who did and did
not report having had COVID-19 and other comparison
groups, using Wilcoxon rank-sum nonparametric test
(continuous parameters) or Pearson's chi-square test
(categorical parameters). Independent predictors of the
self-reported health score were assessed using a generalized linear regression. All analyses were run in SAS
9.4 (SAS Institute, Cary, NC, USA). Statistical significance was determined by two-tailed p < 0.05.

R ESULTS
As of June 2021, the GLR included 10,500 enrollees.
Of these, 2500 patients with CLD (mean ± SD age,
49 ± 13 years; 53% men) from seven countries (Turkey,
India, Egypt, United States, Mexico, Malaysia, and
Pakistan) completed the Covid-GRQ survey. Of these
patients, 20% had CHB, 14% CHC, and 66% NAFLD.
The general characteristics of the study participants
are shown in Table 1.
Of all survey completers, 232 (9.3%) reported having had COVID-19 (Table 1). Of those infected, 86%
reported being diagnosed by a laboratory test, 93%
had at least one symptom, and 75% received treatment
for their symptoms. The mean duration of illness was
12.5 ± 10.5 days; 64% reported receiving antiviral treatment, 19% were hospitalized, 13% needed oxygen support, but none required mechanical ventilation (Table 2).
Regardless of their personal COVID-
19 history,
11.3% of all survey completers reported that the pandemic had an impact on their liver disease (p = 0.37,
between those who were and were not infected); the
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majority of those (73%) reported delays in follow-up
care (Table 2). The LDEP questionnaire included in
the survey confirmed that 81% of patients infected
with COVID-19 versus 69% of patients without a history of COVID-19 infection (p = 0.0001) experienced
worsening in at least one aspect of their life (Table 2).
The most substantial worsening was observed for social life (74% infected vs. 61% not infected), exercise
(51% vs. 42%), and financial situation (37% vs. 30%)
(all p < 0.025; Figure 1). In addition, self-
assessed
health scores were lower in patients with a history of
COVID-19 than in those without (mean ± SD, 6.7 ± 2.2
vs. 7.4 ± 2.2, respectively; p < 0.0001) despite similar
scores reported if there were no pandemic (mean ± SD,
8.5 ± 1.4 vs. 8.4 ± 1.6, respectively; p = 0.59; Table 2). In
both groups, current health scores were lower in comparison to patients' own assessments if there were no
pandemic (both p < 0.0001).
Comparison across the seven countries of origin for
the survey completers showed that the highest rate of
COVID-19 infection was observed in Turkey (12%) while
the lowest rate was seen among GLR participants from
Egypt (<1%; Table S1). Among all survey completers
regardless of their COVID-
19 history, patients from
Mexico and Pakistan reported the greatest impact of
the pandemic on their liver disease (38%), primarily
owing to limited access to routine care. The same patients also reported the highest rate of needing supportive care during the pandemic (defined as specialized
care to support the patient and their family members
cope with the situation and help improve symptoms and
quality of life) (range, 18%–21%; Table S1). Patients
from Pakistan also had the lowest self-reported health
scores (mean, 4.2 on a 1–10 scale).
After adjustment for country of enrollment, liver disease etiology and severity (FIB-
4 score), age, sex,
BMI, diabetes, and history of psychiatric comorbidities
in multivariable analysis, having had COVID-
19 was
found to be independently associated with lower self-
reported health scores (beta = −0.71 ± 0.14 on a 1–10
scale, p < 0.0001).

D I SCUSS I O N
In this global study in which 2500 patients with CLD
completed a survey about their experience with
COVID-19, we found that approximately one in 10 had
contracted COVID-19 by the time of completion and, of
those, almost 20% were hospitalized but none required
mechanical ventilation. The most common form of CLD
in this study was NAFLD or NASH and, as such, patients with these diseases represented the majority of
patients from the GLR who contracted COVID-19.
Of particular interest was that 93% of those infected
with COVID-19 reported having at least one symptom
and 75% received some type of treatment, with 64%
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Comparison of Global Liver Registry patients who reported having versus not having had COVID-19
Positive history of
COVID-19

Negative history of
COVID-19

232

2268

Chronic hepatitis B

59 (25.4%)

430 (19.0%)

0.0179

489 (19.6%)

Chronic hepatitis C

10 (4.3%)

347 (15.3%)

<0.0001

357 (14.3%)

NAFLD or NASH

163 (70.3%)

1491 (65.7%)

Turkey

181 (78.0%)

1299 (57.3%)

India

13 (5.6%)

134 (5.9%)

0.85

147 (5.9%)

Egypt

1 (0.4%)

267 (11.8%)

<0.0001

268 (10.7%)

United States

22 (9.5%)

387 (17.1%)

0.0029

409 (16.4%)

Mexico

4 (1.7%)

46 (2.0%)

0.75

50 (2.0%)

Malaysia

1 (0.4%)

25 (1.1%)

0.34

26 (1.0%)

Pakistan

10 (4.3%)

110 (4.9%)

0.71

120 (4.8%)

Age, years

47.4 ± 10.7

49.1 ± 12.7

0.0497

48.9 ± 12.6

Male sex

115 (52.5%)

1121 (52.7%)

0.96

1236 (52.7%)

Employed

91 (47.4%)

731 (43.9%)

0.35

822 (44.2%)

27 (13.8%)

280 (16.8%)

0.30

307 (16.5%)

Number

p value

All
participants
2500

Chronic liver disease etiology

0.17

1654 (66.2%)

Country
<0.0001

1480 (59.2%)

Baseline medical history:
Cirrhosis by biopsy or elastography
2

Body mass index, kg/m

32.4 ± 7.3

31.1 ± 6.7

0.0337

31.2 ± 6.8

Type 2 diabetes

82 (37.6%)

750 (36.5%)

0.75

832 (36.6%)

Anxiety or panic disorder

75 (34.4%)

610 (29.6%)

0.14

685 (30.0%)

Depression or mood disorder

40 (18.5%)

272 (13.6%)

0.05

312 (14.1%)

Clinically overt fatigue

106 (48.8%)

783 (38.0%)

0.0019

889 (39.0%)

Total FACIT-F score (0–160)

116.6 ± 27.0

117.3 ± 26.8

0.76

117.3 ± 26.9

Note: Data show numbers (percentage) or mean ± SD.
Abbreviations: COVID-19, coronavirus 2019; FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; NAFLD, nonalcoholic fatty liver disease;
NASH, nonalcoholic steatohepatitis.

treated with antiviral drugs (e.g., remdisivir, oseltamivir/tamiflu, avigan/favipiravir, lopinavir–
ritonavir) and
13% requiring oxygen support. Notably, 77% patients
enrolled in Turkey and 80% in Pakistan reported having received antiviral treatment versus less than 10% in
the United States (p < 0.0001). This may reflect regional
differences in COVID-19 management or changes in
treatment over time occurring along with local surges
of infections in specific geographic areas.
In addition to clinical data, we also gathered self-
reported health scores from the survey completers. In
fact, in our multivariable regression analysis, having had
COVID-19 infection was independently associated with
lower self-reported health scores. Furthermore, nearly
60% of those who had COVID-19 reported that they
had at least some difficulty performing daily activities.
These findings about patients with CLD included in this
study are in line with what is known about COVID-19 in
the general population.
Another interesting finding of our study comes from
the perceived impact of the COVID-19 pandemic on
patients' lives regardless of their personal infection

history. In this context, we found that almost 70% of
our study population stated that at least one aspect of
their life worsened because of COVID-19 and over 60%
reported detrimental consequences on their social and
interpersonal interactions. We also attempted to quantify the impact of COVID-19 on the delivery of routine
care, which is essential for patients with CLD. As such,
we found that 11.3% reported that the pandemic had
a negative impact on their liver disease, and the vast
majority of those reported delays in follow-up care; notably, there was no difference between those with and
without a history of actual infection. This is a disturbing
finding that, however, is in accordance with a recent
study that reported a 40% reduction in the routine monitoring of CLD to include HCC surveillance during the
pandemic.[12] It is important to note that the latter can
lead to a rise in adverse and lethal outcomes given that
the doubling time for HCC tumor volume is less than
90 days.[13] In addition, delayed care has been shown to
increase liver-related mortality even without developing
HCC.[14] These findings could help policy makers plan
for future public health emergencies when determining
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Responses to Covid-GRQ by Global Liver Registry participants who reported having versus not having had COVID-19
Positive history of
COVID-19

Negative history of
COVID-19

p value

All
participants

COVID-19 pandemic had any impact on liver
disease (yes/no)

21 (9.1%)

260 (11.6%)

0.25

281 (11.3%)

Had difficulty in access to medical care

10 (4.3%)

88 (3.9%)

0.77

98 (4.0%)

Delayed follow-up care

16 (6.9%)

189 (8.4%)

0.42

205 (8.3%)

Had difficulty in access to laboratory tests

8 (3.4%)

110 (4.9%)

0.32

118 (4.8%)

Needed supportive care during the pandemic

36 (15.7%)

210 (9.5%)

0.0027

246 (10.0%)

Self-reported overall health given the
pandemic situation (1–10)

6.73 ± 2.15

7.36 ± 2.17

<0.0001

7.30 ± 2.17

Self-reported overall health if there were no
pandemic (1–10)

8.47 ± 1.42

8.37 ± 1.59

0.59

8.38 ± 1.57

LDEP change score (0–6)

2.28 ± 1.31

2.13 ± 1.32

0.20

2.15 ± 1.32

LDEP trend score (−3 to +3)

−0.26 ± 1.05

−0.11 ± 0.94

<0.0001

−0.13 ± 0.95

LDEP trend: food/nutrition got worse

48 (20.7%)

369 (16.3%)

0.09

417 (16.7%)

LDEP trend: exercise got worse

118 (50.9%)

952 (42.2%)

0.0113

1070 (43.0%)

LDEP trend: social got worse

172 (74.1%)

1363 (60.5%)

<0.0001

1535 (61.8%)

LDEP trend: vocation/education got worse

37 (15.9%)

258 (11.5%)

0.0438

295 (11.9%)

LDEP trend: financial got worse

86 (37.2%)

674 (30.0%)

0.0229

760 (30.7%)

LDEP trend: housing got worse

13 (5.6%)

113 (5.0%)

0.70

126 (5.1%)

LDEP trend: health care got worse

65 (28.1%)

606 (26.9%)

0.69

671 (27.0%)

LDEP: at least one aspect got worse

188 (81.0%)

1553 (68.8%)

0.0001

1741 (69.9%)

216 (93.1%)

NA

Covid-GRQ item

LDEP

COVID-19-specific items:
Had at least one COVID-19 symptom
Received treatment for COVID-19

156 (75.0%)

NA

Was diagnosed based on a positive test

174 (86.1%)

NA

Duration of illness, days

12.5 ± 10.6

NA

Received treatment with antivirals

145 (64.4%)

NA

Was hospitalized

42 (18.5%)

NA

Required oxygen support

30 (13.2%)

NA

Had no difficulty performing daily activities

98 (43.2%)

NA

Received supportive care while ill

96 (41.6%)

NA

Note: Data show numbers (percentage) or mean ± SD.
Abbreviations: COVID-19, coronavirus 2019; Covid-GRQ, corona virus disease-Global Registry Questionnaire; LDEP, Life Disruption Event Perception; NA,
not applicable.

how to keep access to health care open for all while
also dealing with the emergency rather than trading
one disease for another.
Several caveats of our investigation need to be considered. First, our study is only representative of those
patients who chose to respond to the survey so our
findings may not be representative of all patients with
CLD, particularly those who died or remained too disabled post-COVID-19 infection to respond to our survey
invitation. There was only a small number of participating sites from a few countries with inherent enrollment
biases and varying COVID-19 burden across regions.
This poses a limitation regarding the ability to generalize our conclusions. However, the information we have

provided here is beneficial in understanding the impact of an acute and potentially severe disease among
those who suffer with a chronic disease as well as providing the impact of COVID-19 among patients from
around the world. The study also did not cover periods
of universal availability of COVID-19 vaccines and of
the spread of more contagious severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants that
left larger proportions of most populations with a history
of the infection or vaccine-induced immunity or both; either of those could have affected patients' experience
with the infection. We also acknowledge that because
this study was cross-sectional in design, we were unable to determine long-term outcomes from COVID-19,
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F I G U R E 1 Life Disruption Event Perception scores by history of COVID-19 among Global Liver Registry participants. (A) To what
degree have your life and habits changed in each of these categories since the beginning of the pandemic? (B) Compared to before
the pandemic, how do you view the changes to each life category? COVID-19, coronavirus 2019.

especially among those who reported a significant negative impact from the infection. Thus, we believe that
further research is warranted, but this study has provided a basis from which further comparisons can be
made. Finally, the survey was all self-reported and, as
such, the responses are biased toward a patient's ability to recall their experience.
In summary, we have described the impact of the
COVID-19 pandemic on patients with CLD from seven different countries around the world. We found that over half
of all patients reported that the COVID-19 pandemic had
a detrimental effect on their ability to be socially active, although a higher percentage was noted among those who
had a COVID-19 infection. Perhaps most disturbing was
that some patients reported that COVID-19 negatively impacted their CLD care, primarily through delays in follow-up
care. Given that timely access to both routine and urgent
health care is essential for patients with CLD, policy-maker
efforts must focus on how to effectively continue to deliver
care even during a public health emergency.
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